Jin Seok Ahn

Prof. Jin Seok Ahn

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JCJang Ho Cho
Jang Ho Cho
SLSung Hee Lim
Sung Hee Lim
HAHo Jung An
Ho Jung An
KKKi Hwan Kim
Ki Hwan Kim
KPKeon Uk Park
Keon Uk Park
MAMyung-Ju Ahn
Myung-Ju Ahn
PURPOSE: Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations. PATIENT AND METHODS: This was a multicenter, single-arm, open-label, phase II study in Korea. Patients with histologically confirmed metastatic or recurrent NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R and T790M mutations, and exon 20 insertion were eligible for the study. The primary end point of objective response rate was assessed every 6 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary end points were progression-free survival, overall survival, duration of response, and safety. RESULTS: Between March 2016 and October 2017, 37 patients were enrolled. All were evaluable except one patient who withdrew consent after starting treatment. Median age was 60 years, and 22 (61%) were male. Among patients, 61% received osimertinib as first-line therapy. The mutations identified were G719X (n = 19; 53%), followed by L861Q (n = 9; 25%), S768I (n = 8; 22%), and others (n = 4; 11%). Objective response rate was 50% (18 of 36 patients; 95% CI, 33% to 67%). Median progression-free survival was 8.2 months (95% CI, 5.9 to 10.5 months), and median overall survival was not reached. Median duration of response was 11.2 months (95% CI, 7.7 to 14.7 months). Adverse events of any grade were rash (n = 11; 31%), pruritus (n = 9; 25%), decreased appetite (n = 9; 25%), diarrhea (n = 8; 22%), and dyspnea (n = 8; 22%), but all adverse events were manageable. CONCLUSION: Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.

10 April 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
SPSehhoon Park
Sehhoon Park
TKTae Min Kim
Tae Min Kim
JHJi-Youn Han
Ji-Youn Han
GLGyeong-Won Lee
Gyeong-Won Lee
BSByoung Yong Shim
Byoung Yong Shim
MAMyung-Ju Ahn
Myung-Ju Ahn
PURPOSE: In the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation, the role of anti–PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase III study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP ) in EGFR- or ALK-rearranged or translocated NSCLC upon progression on TKI therapy. MATERIALS AND METHODS: We compared the clinical efficacy of ABCP followed by maintenance therapy with atezolizumab plus bevacizumab with pemetrexed plus carboplatin or cisplatin (PC) followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS). RESULTS: A total of 228 patients with activating EGFR mutation (n = 215) or ALK translocation (n = 13) were enrolled from 16 sites in the Republic of Korea and randomly assigned at 2:1 ratio to either ABCP (n = 154) or PC arm (n = 74). The median follow-up duration was 26.1 months (95% CI, 24.7 to 28.2). Objective response rates (69.5% v 41.9%, P < .001) and median PFS (8.48 v 5.62 months, hazard ratio [HR], 0.62 [95% CI, 0.45 to 0.86]; P = .004) were significantly better in the ABCP than PC arm. PFS benefit increased as PD-L1 expression increased, with an HR of 0.47, 0.41, and 0.24 for PD-L1 ≥1%, ≥10%, and ≥50%, respectively. Overall survival was similar between ABCP and PC arm (20.63 v 20.27 months, HR, 1.01 [95% CI, 0.69 to 1.46]; P = .975). The safety profile of the ABCP arm was comparable with that previously reported, with no additional safety signals, but higher rates of treatment-related adverse events were observed compared with the PC arm. CONCLUSION: To our knowledge, this study is the first randomized phase III study to demonstrate the clinical benefit of anti–PD-L1 antibody in combination with bevacizumab and chemotherapy in patients with EGFR- or ALK-rearranged or translocated NSCLC who have progressed on relevant targeted therapy.

1 April 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KKKyung Hwan Kim
Kyung Hwan Kim
JCJinhyun Cho
Jinhyun Cho
BKBo Mi Ku
Bo Mi Ku
JKJiae Koh
Jiae Koh
JSJong-Mu Sun
Jong-Mu Sun
ESEui-Cheol Shin
Eui-Cheol Shin
Purpose: To investigate blood-based dynamic biomarkers that predict responses to anti-PD-1 therapy in solid tumors. Experimental Design: Pre-planned biomarker analysis was performed as part of a phase II clinical trial (NCT02607631)in patients with metastatic or refractory thymic epithelial tumors (TETs; n= 31) who received pembrolizumab. The biomarker was further tested in an independent cohort of prospectively recruited patients with metastatic non-small cell lung cancer (NSCLC) who received pembrolizumab or nivolumab (NSCLC cohort 1; n= 33) and validated in an independent cohort of patients with NSCLC (NSCLC cohort 2; n= 46). Peripheral blood samples were obtained immediately before treatment (D0) and 7 days after the first dose (D7) and analyzed using multi-color flow cytometry. Results: A higher fold-change in the percentage of Ki-67+cells among PD-1+CD8+T cells 7 days after the first dose (Ki-67D7/D0) significantly predicted durable clinical benefit (DCB;P < 0.001) and prolonged progression-free survival (PFS; P=0.027) in patients with TET. Ki-67D7/D0≥ 2.8 was also associated with better DCB, PFS, and overall survival (OS) in NSCLC cohort 1 (all P< 0.05). Ki-67D7/D0was subsequently validated in NSCLC cohort 2, and Ki-67D7/D0≥ 2.8 significantly predicted better DCB (P=0.001), PFS (P=0.002), and OS (P=0.037). Ki-67D7/D0had a low correlation with tumor PD-L1 expression and combining both factors did not improve the predictive power of Ki-67D7/D0. Conclusions: The proliferative response of peripheral blood PD-1+CD8+T cells, measured as the fold-change in the percentage of Ki-67+cells 7 days after treatment (Ki-67D7/D0), may be a useful surrogate biomarker for predicting the response and prognosis to anti-PD-1 therapy in solid tumors.

1 October 2020 in Annals of Oncology
Verified
Journal Article
Closed access
SPS. Park
S. Park
MLM.-H. Lee
M.-H. Lee
MSM. Seong
M. Seong
SKS.T. Kim
S.T. Kim
JKJ.-H. Kang
J.-H. Kang
JAJin Seok Ahn
Jin Seok Ahn

1 March 2012 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YKYoungwook Kim
Youngwook Kim
JKJeonghun Ko
Jeonghun Ko
ZCZhengYun Cui
ZhengYun Cui
AAAmir Abolhoda
Amir Abolhoda
JAJin Seok Ahn
Jin Seok Ahn
KPKeunchil Park
Keunchil Park
Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors. Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear. Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line. Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clinical case. The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiologically prevent the emergence of cells that are still dependent on EGFR signaling. This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs. Mol Cancer Ther; 11(3); 784–91. ©2012 AACR.

24 February 2017 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
MAMyung-Ju Ahn
Myung-Ju Ahn
JSJong-Mu Sun
Jong-Mu Sun
SLSe-Hoon Lee
Se-Hoon Lee
JAJin Seok Ahn
Jin Seok Ahn
KPKeunchil Park
Keunchil Park
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) has significantly improved clinical outcomes compared with chemotherapy in non-small cell lung cancer (NSCLC) patients with sensitizing EGFR gene mutation. Areas covered: Almost all patients treated with EGFR TKIs eventually develop acquired resistance. It has been reported that activation of the oncogenic EGFR pathway enhances susceptibility of the lung tumors to PD-1 blockade in mouse model, suggesting combination of PD1 blockade with EGFR TKIs may be a promising therapeutic strategy. Nivolumab combined with erlotinib was associated with 19% of grade 3 toxicities. The combination of osimertinib plus durvalumab in pretreated or chemo naïve NSCLC patients showed encouraging clinical activity, however, this combination was associated with high incidence of interstitial lung disease (38%), leading to termination of further enrollment. The combination of gefitinib plus durvalumab demonstrated encouraging activity but higher incidence of grade 3/4 liver enzyme elevation (40–70%). The treatment related Grade 3–4 adverse events were observed in 39% of patients when treated with atezolizumab plus erlotinib. Expert opinion: Given the relatively high incidence of treatment-related toxicities associated with combination of EGFR TKI and immunotherapy, further development of this approach remains controversial. Until now, the combination of EGFR TKI and immunotherapy should be investigational.